JV Melo is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, JV Melo has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in JV Melo's work include Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (5 papers). JV Melo is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (5 papers). JV Melo collaborates with scholars based in United Kingdom, Australia and France. JV Melo's co-authors include Nicholas C.P. Cross, JM Goldman, JM Goldman, Daniel Catovsky, Valérie Lagarde, F-X Mahon, Sally M. Pittman, M. Pomfret, Jesús F. San Miguel and Mark A. Kirkland and has published in prestigious journals such as Blood, Leukemia and Immunology and Cell Biology.
In The Last Decade
JV Melo
16 papers
receiving
1.1k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]
This map shows the geographic impact of JV Melo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JV Melo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JV Melo more than expected).
This network shows the impact of papers produced by JV Melo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JV Melo. The network helps show where JV Melo may publish in the future.
Co-authorship network of co-authors of JV Melo
This figure shows the co-authorship network connecting the top 25 collaborators of JV Melo.
A scholar is included among the top collaborators of JV Melo based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with JV Melo. JV Melo is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
17 of 17 papers shown
1.
Chuah, Charles, et al.. (2003). Zoledronate is active against imatinib mesylate-resistant chronic myeloid leukemia cell lines and synergistic/additive when combined with imatinib mesylate.. UCL Discovery (University College London).2 indexed citations
Melo, JV. (1996). The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]. Blood. 88(7). 2375–2384.530 indexed citations breakdown →
5.
Hochhaus, Andreas, et al.. (1996). Expression of the LH2 gene in chronic myeloid leukaemia cells.. PubMed. 10(7). 1122–6.3 indexed citations
Kirkland, Mark A., et al.. (1994). Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.. PubMed. 8(12). 2156–62.46 indexed citations
Melo, JV & JM Goldman. (1992). Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.. PubMed. 6(8). 786–90.4 indexed citations
Melo, JV, et al.. (1984). The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies.. PubMed. 11(4). 381–5.34 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.